Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 102 articles:
HTML format
Text format



Single Articles


    February 2018
  1. JIMENEZ-MENDOZA E, Vazquez-Salas RA, Barrientos-Gutierrez T, Reynales-Shigematsu LM, et al
    Smoking and prostate cancer: a life course analysis.
    BMC Cancer. 2018;18:160.
    PubMed     Text format     Abstract available


  2. FORT RS, Matho C, Geraldo MV, Ottati MC, et al
    Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
    BMC Cancer. 2018;18:127.
    PubMed     Text format     Abstract available


    January 2018
  3. LANGE M, Laviec H, Castel H, Heutte N, et al
    Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
    BMC Cancer. 2018;18:110.
    PubMed     Text format     Abstract available


  4. SANGHERA S, Coast J, Martin RM, Donovan JL, et al
    Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
    BMC Cancer. 2018;18:84.
    PubMed     Text format     Abstract available


  5. GUERTIN MH, Robitaille K, Pelletier JF, Duchesne T, et al
    Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-c
    BMC Cancer. 2018;18:64.
    PubMed     Text format     Abstract available


  6. CHEN CB, Eskin M, Eurich DT, Majumdar SR, et al
    Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:65.
    PubMed     Text format     Abstract available


  7. HEUMANN A, Heinemann N, Hube-Magg C, Lang DS, et al
    High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
    BMC Cancer. 2018;18:37.
    PubMed     Text format     Abstract available


  8. BOTTCHER R, Kweldam CF, Livingstone J, Lalonde E, et al
    Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
    BMC Cancer. 2018;18:8.
    PubMed     Text format     Abstract available


  9. PESTOVA K, Koch AJ, Quesenberry CP, Shan J, et al
    Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance.
    BMC Cancer. 2018;18:2.
    PubMed     Text format     Abstract available


    December 2017
  10. YANG KQ, Liu Y, Huang QH, Mo N, et al
    Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth.
    BMC Cancer. 2017;17:878.
    PubMed     Text format     Abstract available


  11. DAMODARAN S, Damaschke N, Gawdzik J, Yang B, et al
    Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
    BMC Cancer. 2017;17:874.
    PubMed     Text format     Abstract available


  12. BEEBE-DIMMER JL, Yee C, Paskett E, Schwartz AG, et al
    Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative.
    BMC Cancer. 2017;17:848.
    PubMed     Text format     Abstract available


  13. EGGLY S, Hamel LM, Heath E, Manning MA, et al
    Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.
    BMC Cancer. 2017;17:807.
    PubMed     Text format     Abstract available


    November 2017
  14. KANG YJ, Jang WS, Kwon JK, Yoon CY, et al
    Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
    BMC Cancer. 2017;17:789.
    PubMed     Text format     Abstract available


  15. SAIFUDDIN SR, Devlies W, Santaolalla A, Cahill F, et al
    King's Health Partners' Prostate Cancer Biobank (KHP PCaBB).
    BMC Cancer. 2017;17:784.
    PubMed     Text format     Abstract available


  16. TSAI HK, Lehrer J, Alshalalfa M, Erho N, et al
    Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    BMC Cancer. 2017;17:759.
    PubMed     Text format     Abstract available


  17. CINDOLO L, Natoli C, De Nunzio C, De Tursi M, et al
    Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.
    BMC Cancer. 2017;17:753.
    PubMed     Text format     Abstract available


  18. ENDZELINS E, Berger A, Melne V, Bajo-Santos C, et al
    Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients.
    BMC Cancer. 2017;17:730.
    PubMed     Text format     Abstract available


  19. JIANN BP
    Does hair dye use really increase the risk of prostate cancer?
    BMC Cancer. 2017;17:724.
    PubMed     Text format     Abstract available


    October 2017
  20. KIRKMAN M, Young K, Evans S, Millar J, et al
    Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia.
    BMC Cancer. 2017;17:704.
    PubMed     Text format     Abstract available


  21. IZUMI K, Mizokami A, Namiki M, Inoue S, et al
    Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
    BMC Cancer. 2017;17:677.
    PubMed     Text format     Abstract available


  22. WITTMANN D, Mehta A, Northouse L, Dunn R, et al
    TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial.
    BMC Cancer. 2017;17:664.
    PubMed     Text format     Abstract available


    September 2017
  23. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Text format     Abstract available


  24. FRANKLAND J, Brodie H, Cooke D, Foster C, et al
    Follow-up care after treatment for prostate cancer: protocol for an evaluation of a nurse-led supported self-management and remote surveillance programme.
    BMC Cancer. 2017;17:656.
    PubMed     Text format     Abstract available


  25. PASCALE M, Azinwi CN, Marongiu B, Pesce G, et al
    The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.
    BMC Cancer. 2017;17:651.
    PubMed     Text format     Abstract available


  26. SONG W, Soni V, Soni S, Khera M, et al
    Testosterone inhibits the growth of prostate cancer xenografts in nude mice.
    BMC Cancer. 2017;17:635.
    PubMed     Text format     Abstract available


  27. GONNISSEN A, Isebaert S, Perneel C, McKee CM, et al
    Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer.
    BMC Cancer. 2017;17:634.
    PubMed     Text format     Abstract available


  28. MITRA R, Le TT, Gorjala P, Goodman OB Jr, et al
    Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
    BMC Cancer. 2017;17:631.
    PubMed     Text format     Abstract available


  29. WANG H, Gu L, Wu Y, Feng D, et al
    The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score >/= 7 prostate cancer from group of biopsy-based Gleason score </= 6.
    BMC Cancer. 2017;17:629.
    PubMed     Text format     Abstract available


  30. TANAKA N, Nakai Y, Miyake M, Anai S, et al
    Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.
    BMC Cancer. 2017;17:616.
    PubMed     Text format     Abstract available


    August 2017
  31. KINNUNEN PTT, Murtola TJ, Talala K, Taari K, et al
    Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
    BMC Cancer. 2017;17:585.
    PubMed     Text format     Abstract available


  32. TANAKA N, Asakawa I, Nakai Y, Miyake M, et al
    Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
    BMC Cancer. 2017;17:573.
    PubMed     Text format     Abstract available


  33. QIU J, Peng S, Si-Tu J, Hu C, et al
    Erratum to: Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    BMC Cancer. 2017;17:569.
    PubMed     Text format    


  34. LANGE M, Laviec H, Castel H, Heutte N, et al
    Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
    BMC Cancer. 2017;17:549.
    PubMed     Text format     Abstract available


  35. BECKMANN KR, Vincent AD, O'Callaghan ME, Cohen P, et al
    Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings.
    BMC Cancer. 2017;17:537.
    PubMed     Text format     Abstract available


  36. LAO C, Edlin R, Rouse P, Brown C, et al
    The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
    BMC Cancer. 2017;17:529.
    PubMed     Text format     Abstract available


    July 2017
  37. JACOBSEN F, Taskin B, Melling N, Sauer C, et al
    Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.
    BMC Cancer. 2017;17:504.
    PubMed     Text format     Abstract available


  38. CRAWLEY D, Chandra A, Loda M, Gillett C, et al
    Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
    BMC Cancer. 2017;17:494.
    PubMed     Text format     Abstract available


  39. GRANT DJ, Chen Z, Howard LE, Wiggins E, et al
    UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.
    BMC Cancer. 2017;17:463.
    PubMed     Text format     Abstract available


    June 2017
  40. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Text format     Abstract available


    May 2017
  41. TAN G, Qiu M, Chen L, Zhang S, et al
    JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells.
    BMC Cancer. 2017;17:376.
    PubMed     Text format     Abstract available


  42. MANCARELLA C, Casanova-Salas I, Calatrava A, Garcia-Flores M, et al
    Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
    BMC Cancer. 2017;17:367.
    PubMed     Text format     Abstract available


  43. QIU J, Peng S, Si-Tu J, Hu C, et al
    Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    BMC Cancer. 2017;17:360.
    PubMed     Text format     Abstract available


  44. HABL G, Straube C, Schiller K, Duma MN, et al
    Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    BMC Cancer. 2017;17:361.
    PubMed     Text format     Abstract available


  45. KAWAKAMI K, Fujita Y, Matsuda Y, Arai T, et al
    Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer.
    BMC Cancer. 2017;17:316.
    PubMed     Text format     Abstract available


    April 2017
  46. KIRBY MK, Ramaker RC, Roberts BS, Lasseigne BN, et al
    Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.
    BMC Cancer. 2017;17:273.
    PubMed     Text format     Abstract available


  47. NGOLLO M, Lebert A, Daures M, Judes G, et al
    Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression.
    BMC Cancer. 2017;17:261.
    PubMed     Text format     Abstract available


    March 2017
  48. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Text format     Abstract available


  49. KEALL P, Nguyen DT, O'Brien R, Booth J, et al
    Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial.
    BMC Cancer. 2017;17:180.
    PubMed     Text format     Abstract available


  50. DENSLOW A, Switalska M, Nowak M, Maciejewska M, et al
    The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.
    BMC Cancer. 2017;17:177.
    PubMed     Text format     Abstract available


  51. CHEN L, Wolff DW, Xie Y, Lin MF, et al
    Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5.
    BMC Cancer. 2017;17:179.
    PubMed     Text format     Abstract available


  52. LUNDON DJ, Boland A, Prencipe M, Hurley G, et al
    The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
    BMC Cancer. 2017;17:163.
    PubMed     Text format     Abstract available


    February 2017
  53. CHEVRIER M, Bobbala D, Villalobos-Hernandez A, Khan MG, et al
    Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.
    BMC Cancer. 2017;17:157.
    PubMed     Text format     Abstract available


  54. KUMAR SR, Bryan JN, Esebua M, Amos-Landgraf J, et al
    Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
    BMC Cancer. 2017;17:158.
    PubMed     Text format     Abstract available


  55. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Text format     Abstract available


  56. LAZARO-IBANEZ E, Lunavat TR, Jang SC, Escobedo-Lucea C, et al
    Distinct prostate cancer-related mRNA cargo in extracellular vesicle subsets from prostate cell lines.
    BMC Cancer. 2017;17:92.
    PubMed     Text format     Abstract available


    January 2017
  57. DEMARK-WAHNEFRIED W, Nix JW, Hunter GR, Rais-Bahrami S, et al
    Erratum to: Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing pr
    BMC Cancer. 2017;17:71.
    PubMed     Text format    


  58. BATAI K, Murphy AB, Ruden M, Newsome J, et al
    Race and BMI modify associations of calcium and vitamin D intake with prostate cancer.
    BMC Cancer. 2017;17:64.
    PubMed     Text format     Abstract available


  59. BAGULEY BJ, Skinner TL, Leveritt MD, Wright OR, et al
    Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol.
    BMC Cancer. 2017;17:1.
    PubMed     Text format     Abstract available


    November 2016
  60. LI X, Ji Y, Han G, Li X, et al
    MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer.
    BMC Cancer. 2016;16:894.
    PubMed     Text format     Abstract available


  61. ZHAO J, Stockwell T, Roemer A, Chikritzhs T, et al
    Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis.
    BMC Cancer. 2016;16:845.
    PubMed     Text format     Abstract available


    October 2016
  62. JOHNSTON E, Pye H, Bonet-Carne E, Panagiotaki E, et al
    INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer.
    BMC Cancer. 2016;16:816.
    PubMed     Text format     Abstract available


  63. BJERRE E, Bruun DM, Tolver A, Brasso K, et al
    Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate Community Trial).
    BMC Cancer. 2016;16:767.
    PubMed     Text format     Abstract available


    January 2016
  64. FONAGER RF, Zacho HD, Langkilde NC, Petersen LJ, et al
    (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
    BMC Cancer. 2016;16:10.
    PubMed     Text format     Abstract available


  65. GRAVINA GL, Mancini A, Sanita P, Vitale F, et al
    Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models.
    BMC Cancer. 2016;16:8.
    PubMed     Text format    


  66. KAWAHARA T, Yokomizo Y, Ito Y, Ito H, et al
    Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer.
    BMC Cancer. 2016;16:111.
    PubMed     Text format     Abstract available


  67. UEMURA K, Miyoshi Y, Kawahara T, Yoneyama S, et al
    Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
    BMC Cancer. 2016;16:109.
    PubMed     Text format     Abstract available


  68. MIYOSHI Y, Yoneyama S, Kawahara T, Hattori Y, et al
    Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
    BMC Cancer. 2016;16:128.
    PubMed     Text format     Abstract available


  69. LINDSAY CR, Le Moulec S, Billiot F, Loriot Y, et al
    Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
    BMC Cancer. 2016;16:168.
    PubMed     Text format     Abstract available


  70. HOYNE G, Rudnicka C, Sang QX, Roycik M, et al
    Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer.
    BMC Cancer. 2016;16:151.
    PubMed     Text format     Abstract available


  71. CARTER SL, Centenera MM, Tilley WD, Selth LA, et al
    IkappaBalpha mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
    BMC Cancer. 2016;16:141.
    PubMed     Text format     Abstract available


  72. MENG F, Zhu S, Zhao J, Vados L, et al
    Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
    BMC Cancer. 2016;16:180.
    PubMed     Text format     Abstract available


  73. CARTER SL, Centenera MM, Tilley WD, Selth LA, et al
    Erratum to: IkappaBalpha mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
    BMC Cancer. 2016;16:177.
    PubMed     Text format    


  74. MIKAH P, Krabbe LM, Eminaga O, Herrmann E, et al
    Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    BMC Cancer. 2016;16:214.
    PubMed     Text format     Abstract available


  75. TAI SY, Hsieh HM, Huang SP, Wu MT, et al
    Hair dye use, regular exercise, and the risk and prognosis of prostate cancer: multicenter case-control and case-only studies.
    BMC Cancer. 2016;16:242.
    PubMed     Text format     Abstract available


  76. WANG J, Yang ZH, Chen H, Li HH, et al
    Nemo-like kinase as a negative regulator of nuclear receptor Nurr1 gene transcription in prostate cancer.
    BMC Cancer. 2016;16:257.
    PubMed     Text format     Abstract available


  77. NAKAMURA S, Murakami N, Inaba K, Wakita A, et al
    After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    BMC Cancer. 2016;16:296.
    PubMed     Text format     Abstract available


  78. SCHELTEMA MJ, van den Bos W, de Bruin DM, Wijkstra H, et al
    Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    BMC Cancer. 2016;16:299.
    PubMed     Text format     Abstract available


  79. TAKEDA K, Hara N, Nishiyama T, Tasaki M, et al
    Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    BMC Cancer. 2016;16:332.
    PubMed     Text format     Abstract available


  80. WANG Y, Xu F, Pan J, Zhu Y, et al
    Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
    BMC Cancer. 2016;16:329.
    PubMed     Text format     Abstract available


  81. DE NUNZIO C, Simone G, Brassetti A, Mastroianni R, et al
    Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
    BMC Cancer. 2016;16:407.
    PubMed     Text format     Abstract available


  82. RUSSNES KM, Moller E, Wilson KM, Carlsen M, et al
    Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study.
    BMC Cancer. 2016;16:438.
    PubMed     Text format     Abstract available


  83. LIANG M, Zhan F, Zhao J, Li Q, et al
    CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3.
    BMC Cancer. 2016;16:504.
    PubMed     Text format     Abstract available


  84. KERR L, Rewhorn MJ, Longmuir M, Fraser S, et al
    A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.
    BMC Cancer. 2016;16:529.
    PubMed     Text format     Abstract available


  85. RUANE-MCATEER E, O'Sullivan J, Porter S, Venderbos L, et al
    An exploration of men's experiences of undergoing active surveillance for favourable-risk prostate cancer: A mixed methods study protocol.
    BMC Cancer. 2016;16:586.
    PubMed     Text format     Abstract available


  86. YAMOAH K, Zeigler-Johnson CM, Jeffers A, Malkowicz B, et al
    The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer.
    BMC Cancer. 2016;16:557.
    PubMed     Text format     Abstract available


  87. RUSECKAITE R, Beckmann K, O'Callaghan M, Roder D, et al
    A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease.
    BMC Cancer. 2016;16:607.
    PubMed     Text format     Abstract available


  88. AMARAL CL, Freitas LB, Tamura RE, Tavares MR, et al
    S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.
    BMC Cancer. 2016;16:602.
    PubMed     Text format     Abstract available


  89. SCHOFIELD P, Gough K, Lotfi-Jam K, Bergin R, et al
    Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trial.
    BMC Cancer. 2016;16:637.
    PubMed     Text format     Abstract available


  90. TSOURLAKIS MC, Stender A, Quaas A, Kluth M, et al
    Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.
    BMC Cancer. 2016;16:641.
    PubMed     Text format     Abstract available


  91. WANG K, Wu G, Li J, Song W, et al
    Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis.
    BMC Cancer. 2016;16:674.
    PubMed     Text format     Abstract available


  92. HEIR T, Falk RS, Robsahm TE, Sandvik L, et al
    Cholesterol and prostate cancer risk: a long-term prospective cohort study.
    BMC Cancer. 2016;16:643.
    PubMed     Text format     Abstract available


  93. LEE SO, Kim JS, Lee MS, Lee HJ, et al
    Anti-cancer effect of pristimerin by inhibition of HIF-1alpha involves the SPHK-1 pathway in hypoxic prostate cancer cells.
    BMC Cancer. 2016;16:701.
    PubMed     Text format     Abstract available


  94. DAYYANI F, Zurita AJ, Nogueras-Gonzalez GM, Slack R, et al
    The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.
    BMC Cancer. 2016;16:721.
    PubMed     Text format     Abstract available


  95. MIKI K, Sasaki H, Kido M, Takahashi H, et al
    A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    BMC Cancer. 2016;16:708.
    PubMed     Text format     Abstract available


    January 2015
  96. CAO W, Li F, Yao J, Yu J, et al
    Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.
    BMC Cancer. 2015;15:915.
    PubMed     Text format     Abstract available


  97. GRAVINA GL, Mancini A, Sanita P, Vitale F, et al
    KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models.
    BMC Cancer. 2015;15:941.
    PubMed     Text format     Abstract available


  98. CICIONE A, De Nunzio C, Tubaro A, Cantiello F, et al
    Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study.
    BMC Cancer. 2016;16:59.
    PubMed     Text format     Abstract available


  99. HSIAO JJ, Ng BH, Smits MM, Wang J, et al
    Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
    BMC Cancer. 2015;15:204.
    PubMed     Text format     Abstract available


  100. MENGUAL L, Lozano JJ, Ingelmo-Torres M, Izquierdo L, et al
    Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers.
    BMC Cancer. 2016;16:76.
    PubMed     Text format     Abstract available


  101. DEMARK-WAHNEFRIED W, Nix JW, Hunter GR, Rais-Bahrami S, et al
    Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy
    BMC Cancer. 2016;16:61.
    PubMed     Text format     Abstract available


  102. CAMPTON DE, Ramirez AB, Nordberg JJ, Drovetto N, et al
    High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining.
    BMC Cancer. 2015;15:360.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: